Navigation Links
Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis

at study entry with a mixed form of VKC (87 patients, 73.7%).

Vekacia(R) improved both signs and ocular symptoms of VKC in children who received treatment. The superiority of Vekacia(R) over its vehicle has been demonstrated by the statistically significant improvement of both objective signs of VKC and keratitis in treated patients. Both doses were safe and well tolerated. Local tolerance at instillation was satisfactory and therefore compliance to the recommended dose regimen of four instillations per day was good. Systemic exposure to CsA was negligible in the treated patients. Compliance to the study regimen of four daily instillations of the drug was excellent.

Overall improvement of subjective symptoms (burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge and photophobia) was superior to the vehicle for both concentrations of Vekacia(R). For objective signs (conjunctival erythema/hyperhemia, conjunctival chemosis and discharge, papillae, limbal infiltrates and corneal epithelial disease), there was a statistically significant difference between both concentrations of Vekacia(R) and the vehicle treatment (p=0.0386 and 0.0208 for the Vekacia(R) 0.05% and Vekacia(R) 0.1% treatment arms, respectively). Similarly, improvement in superficial keratitis was statistically significant with Vekacia(R) 0.05% versus vehicle (p=0.0176).

At one month of study, only seven patients had withdrawn from the study, which comprised four patients using the vehicle and three patients using Vekacia(R), including one case of ocular intolerance following study drug instillation. Few treatment-emergent adverse effects (TEAEs) were reported, the most frequent being eye disorders of mild intensity. The tested formulations were rated as comfortable by 94.4% (vehicle), 79.5% (Vekacia(R) 0.05%) and 80.6% (Vekacia(R) 0.1%). Blood levels of CsA were assayed after one month of treatment in 16 patients treated with Vekacia(R) and
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:2/27/2015)... February 27, 2015 ... Überwachungssystem für kongestive Herzinsuffizienz (CHF) in seiner ...     Die ... neuartiges Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz ... sie ein Finanzierungsvorhaben über 5 Mio. USD ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... DESI are increasing in applications as their ... research firm Kalorama Information.  Kalorama Information says ... MS) is the most powerful tool in ... (mass spec; MS) through its traditional techniques ...
(Date:2/26/2015)... Feb. 26, 2015  AbbVie (NYSE: ... studies in its neuroscience and oncology development programs ... th American Academy of Neurology annual meeting ... April 18-25. The accepted abstracts feature results from ... to investigational treatments in AbbVie,s pipeline. Presentations will ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... VEGAS, Jan. 9, 2012 BASIS Science, Inc. ( www.mybasis.com ... and health tracker, the Basis™ B1 band, will be demoing ... showing its web-based personal dashboard for the first time. The ... people information about their everyday health and wellness. ...
... the nation,s largest independent specialty pharmacy in the ... rights from Regeneron for its new drug EYLEA™ ... 2011, EYLEA (aflibercept) Injection was approved by the ... the treatment of neovascular (wet) age-related macular degeneration ...
Cached Medicine Technology:BASIS Science to Demo Basis Band at 2012 International CES; Reveals Design of Web Dashboard 2Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection 2
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 A ... found a correlation between men who cycle on a regular ... overall health, the study suggests that the more hours per ... to develop prostate cancer, leading to an increased importance on ... it allows physicians to look more closely at patents’ risk ...
(Date:2/27/2015)... MD (PRWEB) February 27, 2015 ... (Meso Foundation) and the National Cancer Institute (NCI) ... Mesothelioma at the National Institutes of Health (NIH), ... one part is dedicated to medical professionals and ... is directed to the general public, including patients, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Pipette.com announces ... 2 , price is only valid until the end ... technicians looking for a vortex mixer that allows for ... was founded in 1954 and is headquartered in Bohemia, ... & shakers, as well as other rockers, incubators, and ...
(Date:2/27/2015)... Cary, NC (PRWEB) February 27, 2015 ... nation’s leading cancer research funding organizations, is excited to ... varied ways to participate and many long-standing partnerships highlight ... cancer and focus on expanding ways for all to ... cash donations to cutting-edge cancer research, The V Foundation ...
(Date:2/27/2015)... 2015 According to court documents, Donna ... June 25, 2013 and underwent a procedure during which ... mouth. Because the duodenoscope allegedly had not been ... “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , A lawsuit ... County on behalf of Ms. Pirolli alleging that Lutheran ...
Breaking Medicine News(10 mins):Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... The next time you take aspirin for a headache, ... similar to aspirin, is found in willow tree bark ... defense against pathogens. By mimicking the chemical production processes ... and engineer many important alkaloid drug products, including caffeine, ...
... shot Depo Provera offers a convenient alternative for women who ... research from Arizona State University has shown the shot actually ... medroxyprogesterone acetate (MPA), the hormone active in Depo Provera and ... rodents. The study is currently in press in the journal ...
... HealthDay Reporter , MONDAY, Oct. 31 (HealthDay News) ... report feeling happy and content live longer than others. ... longer life, and the study authors also found that high ... off people,s lives. Still, "the study therefore points ...
... 1 (HealthDay News) --,Pregnant women who have trouble sleeping ... trimesters are more likely to deliver prematurely, according to ... trimester, however, were not associated with increased chances of ... be a connection between sleep and preterm labor, although ...
... PLAINS, N.Y. -- Preterm birth rates improved in almost every ... change was more than 10 percent, according to the March ... three-year improvement in the U.S. preterm birth rate means that ... and spared the risk of life-long health consequences of an ...
... in the November issue of the Journal of ... on the management of incidental findings found on body ... found that is unrelated to the present illness and ... have improved radiologists, ability to identify small or subtle ...
Cached Medicine News:Health News:Plant researchers locate transporter used for nicotine metabolism 2Health News:Hormone in birth control shot linked to memory loss 2Health News:Hormone in birth control shot linked to memory loss 3Health News:Could Happy Lives Be Longer Lives? 2Health News:Could Happy Lives Be Longer Lives? 3Health News:Poor Sleep Might Be Linked to Preterm Labor 2Health News:Preterm birth rate shows three year improvement in most states 2
... etched into the gel tray which casts a ... cables, three 7x10 cm gel trays, 4 aluminum ... The Chameleon can accomodate up to five combs ... of 120 samples with a 2.5 cm path ...
... of a Separation-Control unit for system control ... gel staining. The optional PhastTransfer Kit quickly ... unit. Electrophoresis is performed on a thermostatic ... 0 to +70 C. Multi-step programming capability ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
Medicine Products: